Forest, Daiichi Partner To Promote Hypertension Combo Azor Upon Approval
This article was originally published in PharmAsia News
Executive Summary
Forest Laboratories and Daiichi Sankyo are building upon an ongoing collaboration for Benicar and Benicar HCT with the signing of a new deal to co-promote the fixed-dose antihypertensive Azor, whose approval is anticipated in September. The companies announced the signing of a letter of intent to enter into a collaboration Aug. 21